Study S001786

The Impact of LY2189265 Versus Metformin on Glycemic Control in Early Type 2 Diabetes Mellitus (AWARD-3: Assessment of Weekly AdministRation of LY2189265 in Diabetes-3)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01126580
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 807
Start: 2010-05
Primary completion: 2011-11
Lead sponsor: Eli Lilly and Company
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Metformin; DRUG:LY2189265; DRUG:Placebo (oral); DRUG:Placebo (subcutaneous)
Results posted: TRUE
Secondary identifiers: OTHER:H9X-MC-GBDC; REGISTRY:CTRI/2010/091/003036

Registered primary outcomes

Change From Baseline to 26-week Endpoint in Glycosylated Hemoglobin (HbA1c) [Baseline, 26 weeks]

Linked records (5)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0024857	Metformin monotherapy for adults with type 2 diabetes mellitus. Gnesin F, The Cochrane database of systematic reviews	2020	Systematic review	PMID 32501595 DOI	cites ClinicalTrials.gov:NCT01126580; registry reference DERIVED:32501595
R0020285	Patient-reported outcome results in patients with type 2 diabetes treated with once-weekly dulaglutide: data from the AWARD phase III clinical trial programme. Yu M, Diabetes, obesity & metabolism	2016	Other trial	PMID 26691396 DOI	cites ClinicalTrials.gov:NCT01126580; registry reference DERIVED:26691396
R0025090	Similar efficacy and safety of once-weekly dulaglutide in patients with type 2 diabetes aged ≥65 and <65 years. Boustani MA, Diabetes, obesity & metabolism	2016	Other trial	PMID 27161178 DOI	cites ClinicalTrials.gov:NCT01126580; registry reference DERIVED:27161178
R0022865	Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Umpierrez G, Diabetes care	2014	Randomized trial	PMID 24842985 DOI	cites ClinicalTrials.gov:NCT01126580; registry reference DERIVED:24842985
R0052449	Once-Weekly Dulaglutide Produces Superior Glycemic Control Compared with Metformin Brian D. Hoyle, MD Conference Express	2013	Randomized trial	DOI	cites ClinicalTrials.gov:NCT01126580